TABLE 2.
Primers used in this study
| Primer | Construct or use(s) | Sequencea |
|---|---|---|
| 5′SapA Forward | pMEB078 | CATATCtctagaGCGGATAGCTTAATTTATTGCACCAG |
| 5′SapA Reverse | pMEB078 | CATATCggtaccCATATCctcgagGAATCTTTACTGTATATTCATTCGGTGCTG |
| 3′SapA Forward | pMEB080 | CATATCtctagaGCGGATAGCTTAATTTATTGCACCAG |
| 3′SapA Reverse | pMEB080 | TAAACGAACTTGCCCGAATGGCTC |
| SapAcompFor1 | pMEB108 | GATGTATCATTACTCACTAATATCCCTGCT |
| SapAcompRev1 | pMEB108 | CGGTCGAAATCCAACAGAACACAG |
| SapPromoterFor1 | pMEB114 | CCTTTAATTTGTTCTAAATACATAATGATCC |
| SapPromoterRev1 | pMEB114 | CATATCcatatgTCTTTTCGCCTTAATTTAAGC |
| Sap Forward 2 | Nested RT-PCR | CGGATAATTCGGTGTTGGCGCATT |
| Sap Reverse 3 | Nested RT-PCR | TGTGCACTCGACCTGTATGCGGAT |
| Sap Forward 5 | PCR of clinical isolates | GCATTTCTCATACTGCGGTGGCAA |
| Sap Forward 6 | Nested RT-PCR | AATGCGCATATTGAGCCATTCGGG |
| Sap Reverse 6 | Nested RT-PCR; PCR of clinical isolates | ATCCGAGCGGAATCCCGATAATCA |
a
Restriction enzyme sites are shown in lowercase type and underlined.